RxDoctor Payments Data

Christine Baker, MD

Internal Medicine · Northampton, MANPI 1518946359

Payments from drug & device makers

$1,750in general payments, 2019–2025

Across 105 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$333
  • AstraZeneca$241
  • Pfizer$241
  • Sumitomo Pharma America, Inc.$177
  • E.r. Squibb & Sons, L.L.C.$135
  • AbbVie$109
  • plus $515 from 11 others

What the payments were for

  • Food & beverage$1,750100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,750 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$227,679
Medicare patients
561
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$147,763
XareltoRivaroxaban36$45,368
OxycontinOxycodone Hcl44$44,589
FarxigaDapagliflozin Propanediol28$34,323
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$30,202
OzempicSemaglutide22$29,481
MyrbetriqMirabegron27$28,482
TrulicityDulaglutide11$19,054
GemtesaVibegron14$14,060
Tresiba Flextouch U-100Insulin Degludec12$9,508
Atorvastatin Calcium540$9,234
SynthroidLevothyroxine Sodium113$6,082
Metoprolol Succinate203$5,101
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$4,994
Lisinopril495$4,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$241$153,872173 claims
Johnson & JohnsonXarelto$47$45,36836 claims
GSKTrelegy Ellipta, Anoro Ellipta$333$35,19650 claims
AstraZenecaFarxiga$241$34,32328 claims
Novo NordiskOzempic$92$29,48122 claims
Astellas Pharma US IncMyrbetriq$55$28,48227 claims
Lilly USA, LLCTrulicity$82$19,05411 claims
Sumitomo Pharma America, Inc.Gemtesa$177$14,06014 claims
AbbVieSynthroid$109$6,082113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Northampton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →